
Anti-(vascular endothelial growth factor, VEGF) is a first-line treatment for many retinal vascular diseases leading to macular edema. In clinical practice, repeated intraocular injections is required to achieve therapeutic effects. Intraocular injection is safety, and only few complications such as elevated intraocular pressure and intraocular inflammation have been reported. In recent years, clinicians have gradually begun to pay attention to the effects of repeated injections of anti-VEGF drugs on cornea. It has been reported that anti-VEGF drugs may affect corneal epithelium, corneal endothelium, corneal nerve, corneal biomechanics, dry eye and other aspects, which should be paid attention to by ophthalmologists. ( Int Rev Ophthalmol, 2023, 47: 475-480)
Blue-light filtering introcular lens (IOLs) can effectively filter out some of the short wavelength blue light and are expected to provide protection to the fundus. Research confirms that blue light-filtering IOLs do not significantly affect postoperative color vision, sleep quality, or contrast sensitivity. Several long-term cohort studies have provided new evidence-based medical evidence for retinal protection, but some studies still suggest that blue light-filtering IOLs do not have significant advantages over clear IOLs. ( Int Rev Ophthalmol, 2023, 47: 462-465)
Retinopathy of prematurity (ROP) has already become the leading cause of blindness in children worldwide, while neovascularization is the significant pathological cause of ROP occurrence and development. Except for participating in coagulation and hemostasis, wound healing, inflammation and tumor metastasis, platelets, the cellular debris produced by mature macrophages, play an important role in angiogenesis through regulating angiogenesis related factors and cells. Researchers have shown that the role and variation of platelets in ROP may provide new ideas for early screening and treatment with platelets infusion. ( Int Rev Ophthalmol, 2023, 47: 413-417)
The coronavirus disease 2019 (COVID-19) pandemic has caused a sustained global outbreak with extremely diverse clinical manifestations, affecting multiple organ systems throughout the body, including the eyes. Increasing evidence suggests that COVID-19 may replicate and spread within ocular tissues, leading to ocular symptoms. Ocular symptoms may occur in both the acute infection phase and the autoimmune inflammatory response phase of the infection caused by COVID-19, which may involve various ocular tissues (eyelids, conjunctival, cornea, sclera, lens, and other ocular tissues), presenting as inflammatory and vascular related clinical manifestations. Although whether COVID-19 is transmitted through the eyes is still controversial, protecting eye hygiene and avoiding eye contact with contaminants remains an important prevention and control measure. ( Int Rev Ophthalmol, 2023, 47: 385-391)
Eyelid malignancies are common ocular adnexal malignancies, which can not only affect the patient's vision and appearance, but also have a great threat to the patient's life. In recent years, based on the studies of the Hedgehog pathway, epidermal growth factor receptor (EGFR) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mediated pathways and the immune checkpoint pathway, some targeted agents have shown certain efficacy and safety against eyelid malignancies, such as basal cell carcinoma, cutaneous squamous cell carcinoma, malignant melanoma, and Merkel cell carcinoma. Targeted therapy and immunotherapy provide additional options for patients with eyelid malignancies that recur after surgical resection, progress after systemic therapy, locally advanced or metastatic. Combined therapies have a higher response rate and longer survival than monotherapy. In the future, with the discovery of more downstream targets and better combined therapies, more treatment options will be available for eyelid malignancies. ( Int Rev Ophthalmol, 2023, 47: 436-444)